Torsdag 15 Maj | 00:47:59 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-30 07:30 Kvartalsrapport 2025-Q3
2025-07-10 07:30 Kvartalsrapport 2025-Q2
2025-06-26 N/A Årsstämma
2025-05-23 N/A X-dag ordinarie utdelning QLINEA 0.00 SEK
2025-04-14 - Kvartalsrapport 2025-Q1
2025-04-03 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-12 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-03 - Extra Bolagsstämma 2023
2023-06-13 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Q-Linea grundades 2008 och har huvudkontor i Uppsala.
2023-02-10 13:00:00

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received certification according to the new and more comprehensive EU regulation for in-vitro diagnostic medical devices, IVDR

The certification, issued by the notified body TÜV SÜD, applies to Q-linea's quality management system (QMS) as well as the product groups consumables and analysis software for testing antibiotic resistance.

"I am very happy that we have achieved this high level of quality for our processes and products and that we have achieved IVDR certification at such an early stage. The certification is proof of a comprehensive quality focus in the company and an important basis for the development of new products and updates to existing products on the European market. This clearly gives us a market advantage compared to companies that have not yet achieved IVDR status," says Jonas Jarvius, CEO of Q-linea.

The IVDR certification is a prerequisite for being able to CE-mark ASTar BC G- Kit according to IVDR. The goal is to obtain a CE-mark for ASTar BC G-Kit according to IVDR before the summer. ASTar Instrument is CE-marked according to IVDR since May 2022.

About the IVDR certification
Q-linea's products ASTar Instrument and ASTar BC G- Kit (consumables and analysis software) were first CE-marked according to the directive 98/79/EC for in-vitro diagnostic medical devices in May 2021. The new and more comprehensive regulation for in-vitro diagnostic medical devices, IVDR (EU) 2017/746, entered into force on May 26, 2022, and Q-linea implemented all applicable IVDR requirements and CE-marked ASTar Instrument according to IVDR in May 2022. For products that require a notified body for CE marking according to IVDR, there is an extended transition period, among other things due to the complexity of the new regulation and lack of capacity of notified bodies. However, no significant changes to CE-marked products according to the previous directive may be implemented after May 26, 2022, and no new products may be CE-marked according to the directive during the transition period. For ASTar BC G- Kit, certification by a notified body is required to CE-mark according to IVDR, which is now possible after IVDR certification by TÜV SÜD.

About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.

ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.